# nABCD Simulation Results: Power-Normal Distribution

**Author**: Katrina Bennett
**Date**: 2026-02-03
**Reference**: Goto et al. (1979); Maruo & Goto (2013)

---

## Simulation Parameters

- Sample size: n = 100 per group
- Replications: 100
- Bootstrap: Not used for point estimates (full bootstrap CI in final version)

---

## Section 4.1: Systematic Scenarios

Methodological validation using Power-Normal distribution with varying shape parameter α.

| ID | Description | α₁ | α₂ | μ₁ | μ₂ | σ₁ | σ₂ | nABCD | SD |
|----|-------------|----|----|----|----|----|----|-------|-----|
| S01 | Null: Normal vs Normal | 1 | 1 | 50 | 50 | 10 | 10 | 0.067 | 0.025 |
| S09 | Null: Right-skew (same) | 2 | 2 | 50 | 50 | 10 | 10 | 0.068 | 0.025 |
| S10 | Alt: Right-skew (different) | 2 | 3 | 50 | 50 | 10 | 10 | 0.139 | 0.051 |
| S11 | Null: Left-skew (same) | 0.5 | 0.5 | 50 | 50 | 10 | 10 | 0.063 | 0.020 |
| S12 | Alt: Opposite skew | 0.5 | 2 | 50 | 50 | 10 | 10 | **0.405** | 0.042 |
| S13 | Alt: Mild vs strong skew | 1.5 | 3 | 50 | 50 | 10 | 10 | 0.220 | 0.042 |

### Key Findings (Systematic)

1. **Null scenarios (S01, S09, S11)**: nABCD ≈ 0.06-0.07
   - Represents sampling variability only
   - Consistent across symmetric and skewed distributions
   - Supports use of threshold δ = 0.05 for practical significance

2. **Shape differences detected (S10, S13)**: nABCD = 0.14-0.22
   - Different skewness parameters produce detectable differences
   - Falls in "Small" to "Medium" range

3. **Opposite skew (S12)**: nABCD = 0.41
   - Large distributional difference correctly identified
   - Would recommend separate analysis

---

## Section 4.2: Realistic Scenarios

Clinical relevance demonstration using actual effect modifier characteristics.

| ID | Effect Modifier | Region 1 | Region 2 | nABCD | SD | Interpretation |
|----|-----------------|----------|----------|-------|-----|----------------|
| R01 | BMI | Japan: PN(23, 3, 1.5) | US: PN(28, 5, 2) | **0.484** | 0.025 | **Large** |
| R02 | Age (elderly) | Japan: PN(72, 8, 0.8) | US: PN(68, 10, 1) | 0.119 | 0.045 | Small |
| R03 | eGFR (CKD) | Asia: PN(45, 15, 0.7) | West: PN(50, 18, 0.8) | 0.132 | 0.047 | Small |
| R04 | HbA1c | Asia: PN(7.5, 1.2, 1.8) | West: PN(8.2, 1.5, 2) | 0.291 | 0.041 | Medium-Large |
| R05 | Severity score | Region A: PN(280, 80, 1.5) | Region B: PN(320, 100, 1.8) | 0.270 | 0.044 | Medium |

### Key Findings (Realistic)

1. **BMI (R01)**: nABCD = 0.48 — **Large difference**
   - Japan vs US BMI distributions are substantially different
   - For metabolic drugs where BMI is an effect modifier, **pooling not recommended**
   - Regional stratification or subgroup analysis warranted

2. **Age (R02)**: nABCD = 0.12 — **Small difference**
   - Despite different means (72 vs 68), distributions sufficiently similar
   - Pooling acceptable with possible sensitivity analysis

3. **eGFR (R03)**: nABCD = 0.13 — **Small difference**
   - CKD populations across regions show acceptable similarity
   - Pooling supported

4. **HbA1c (R04)**: nABCD = 0.29 — **Medium-Large difference**
   - Glycemic control differs across regions
   - Pooling with sensitivity analysis; consider stratification

5. **Severity (R05)**: nABCD = 0.27 — **Medium difference**
   - Enrollment criteria may need harmonization
   - Pooling with sensitivity analysis

---

## Clinical Implications

| nABCD Range | Recommendation | Example Scenarios |
|-------------|----------------|-------------------|
| < 0.05 | Strong support for pooling | — |
| 0.05 – 0.15 | Pooling acceptable | Age, eGFR |
| 0.15 – 0.30 | Pool with sensitivity analysis | HbA1c, Severity |
| > 0.30 | Separate analysis recommended | **BMI** |

---

## Acknowledgment

We thank the pioneering work of Dr. Masashi Goto and colleagues on the power-normal distribution, which provides an elegant framework for our simulation studies.

---

*Results generated by Katrina Bennett | 2026-02-03*
